PULMONX CORP
LUNGNASDAQ🏆 #3271 by market capUS Equity
$237.82▲ $15.93 (+6.70%)
Simulated price1h—
24h▲ 6.7%
7d—
14d—
30d—
1y—
🏦Market Cap
$97M
Small Cap
📈Revenue Growth (YoY)
-3.4%
Declining
📊Gross Margin
77.1%
High
💵FCF Margin
—
⚖️P/S Ratio
1.1x
Cheap
Otter Score
63
Fair
No chart data available for LUNG.
Trading Snapshot
- Day Range
- $236.09 – $239.73
- 52-Week Range
- $1.13 – $2.89
- Volume
- $2.69B
- Avg Volume
- $3.18B
- Shares Outstanding
- 42.2M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $87M
- Last Q Revenue
- $22M
- P/E Ratio
- —
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-1.16
- Dividend Yield
- —
Why Investors Own LUNG
- ✓High-growth profile — revenue up +36.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$87M▲ +36.1% YoY
Gross Margin (TTM)
47.2%▲ +1.7% YoY
Operating Income (TTM)
$21M▲ +36.1% YoY
Free Cash Flow (TTM)
$13M▲ +36.1% YoY
About PULMONX CORP
A company profile for PULMONX CORP isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
63/100
Analyst Price Target
ⓘAverage Target
$264.74
▲ +11.3% Upside
High Target$295.56
Low Target$244.94
Based on 14 analysts
Latest News & Updates
🚀
Reuters·2h ago
PULMONX CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift LUNG price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
PULMONX CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.